Biochemistry methods

Immunoassay Market to Reach $43.51 Billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
Tuesday, March 30, 2021
Immunologic tests, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Immunoassay, ELISA, Assay, Siemens Healthineers, Enzyme immunoassay, DiaSorin

Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.

Key Points: 
  • Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.
  • Through all these advances, the usage of immunoassay is further expected to expand, supporting market growth in upcoming years.
  • On the basis of product and solution, the immunoassay kits and reagents segment accounted for the largest share of the overall immunoassays market.
  • For instance, in February 2021, Siemens Healthineers AG (Germany) received the CE mark approval for its SARS-CoV-2 Antigen Assay (CoV2Ag).

Immunoassay Market to Reach $43.51 Billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
Tuesday, March 30, 2021
Immunologic tests, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Immunoassay, ELISA, Assay, Siemens Healthineers, Enzyme immunoassay, DiaSorin

Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.

Key Points: 
  • Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.
  • Through all these advances, the usage of immunoassay is further expected to expand, supporting market growth in upcoming years.
  • On the basis of product and solution, the immunoassay kits and reagents segment accounted for the largest share of the overall immunoassays market.
  • For instance, in February 2021, Siemens Healthineers AG (Germany) received the CE mark approval for its SARS-CoV-2 Antigen Assay (CoV2Ag).

Stable Isotope Labeled Compounds Market Research and Outlook Report - Global Trends, Growth Opportunities and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Chemicals, Plastics, Manufacturing, Physical sciences, Natural sciences, Chemistry, Isotopes, Biochemistry methods, Stable isotope ratio, Lithium

The "Stable Isotope Labeled Compounds Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stable Isotope Labeled Compounds Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Stable Isotope Labeled Compounds market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Stable Isotope Labeled Compounds market types and applications.
  • It is a focused study on Stable Isotope Labeled Compounds market space including global and regional eight-year forecasts for revenues as well as proffers detailed snapshots of country-wide Stable Isotope Labeled Compounds market revenues.
  • The Stable Isotope Labeled Compounds market report presents key trends and dynamics making an impact on the Stable Isotope Labeled Compounds companies across the Americas, Europe, Asia Pacific, and Other markets and provides innovative approaches to stay ahead of the competition in the opportunity-rich Stable Isotope Labeled Compounds market.

Avacta Signs Diagnostic Licensing Deal with Biokit

Retrieved on: 
Tuesday, March 9, 2021
Biotechnology, Manufacturing, Health, Radiology, Pharmaceutical, Oncology, Other Science, Research, Other Manufacturing, Science, Clinical trials, Natural sciences, Medicine, Chemistry, Immunologic tests, Affimer, Biochemistry methods, Medical tests, Immunoassay, Laboratory techniques, Rapid antigen test, Assay, Analyte

The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte.

Key Points: 
  • The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte.
  • Under the terms of the agreement Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners a diagnostic immunoassay for this analyte.
  • Avactas diagnostics business model combines development of a wholly owned pipeline of products, including the SARS-CoV-2 rapid antigen test, with licensing of Affimer reagents to diagnostic development partners such as Biokit.
  • Dr Marta Palicio, Innovation Director of Biokit commented:
    "Biokit is very pleased to have reached this agreement with Avacta.

Global Chemiluminescence Immunoassay Market Analysis, 2020-2027 - Focus on Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease - ResearchAndMarkets.com

Retrieved on: 
Friday, February 26, 2021
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Medicine, Health, Medical specialties, Biochemistry methods, Immunologic tests, Immunoassay, Chemiluminescence, Autoimmune disease, Autoimmunity, Diabetes, Disease

The global chemiluminescence immunoassay market is expected to reach USD 10.67 billion by 2027.

Key Points: 
  • The global chemiluminescence immunoassay market is expected to reach USD 10.67 billion by 2027.
  • Chemiluminescence immunoassay solutions are also used for detection of numerous severe diseases including autoimmune disease, cancer, and diabetes, among others.
  • The global chemiluminescence immunoassay industry is segmented on the basis of product, application, end-use, and region.
  • Based on application, the market is classified as therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease, autoimmune disease, and others.

Bio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio

Retrieved on: 
Wednesday, February 3, 2021
Natural sciences, Physical sciences, Chemistry, Immunologic tests, Biochemistry methods, Laboratory techniques, Biotechnology, Assay, Titration, Microfluidics, Immunoassay

MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to include nine new cartridge formats.

Key Points: 
  • MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to include nine new cartridge formats.
  • These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge.
  • Simple Plex assay cartridges, run on the EllaTM platform, utilizing state-of-the-art microfluidics to deliver a fully automated immunoassay solution.
  • Factory calibration of each Simple Plex assay cartridge eliminates the need to generate standard curves.

Global Antimicrobial Resistance Diagnostics Markets, 2021-2024: New Diagnostic Technologies, Beyond Gene Sequencing Under Development to Capture this Growing Market

Retrieved on: 
Thursday, January 28, 2021
Biochemistry methods, Ion source, Matrix-assisted laser desorption/ionization, Curetis

3.2.8 What Happens to the Microbiology Lab?

Key Points: 

3.2.8 What Happens to the Microbiology Lab?
MALDI-TOF - Results in Minutes, not Days.
Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

Avacta Announces Collaboration Agreement With Bruker

Retrieved on: 
Thursday, January 28, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Biotechnology, Science and technology, Chemistry, Physical sciences, Bruker, Affimer, Biochemistry methods, Matrix-assisted laser desorption/ionization, Billerica, Massachusetts, Assay, Mass spectrometry

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR, Bruker) to evaluate the Affimer-based, bead assisted mass spectrometry (BAMS) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) (Adeptrix).

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR, Bruker) to evaluate the Affimer-based, bead assisted mass spectrometry (BAMS) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc. (Beverley, MA) (Adeptrix).
  • Bruker is one of the worlds leading analytical instrumentation companies providing high-performance scientific instruments and high-value analytical and diagnostic solutions to scientists globally.
  • Alastair Smith, Chief Executive Officer of Avacta Group, commented: I am delighted to have established this collaboration agreement with Bruker to further develop the potential for the BAMS COVID-19 test as a clinical IVD.
  • We will be working closely with Bruker on the clinical assessment of the BAMS assay on Brukers MALDI-TOF instruments.

Gyros Protein Technologies Introduces Gyrolab Bioaffy 4000 CD to Extend Sensitivity of Immunoassay CD Range

Retrieved on: 
Wednesday, January 27, 2021
Medical Supplies, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Natural sciences, Biochemistry methods, Immunologic tests, Chemistry, Physical sciences, Immunoassay, Assay

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab Bioaffy 4000 CD for immunoassay applications in biotherapeutic workflows.

Key Points: 
  • Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab Bioaffy 4000 CD for immunoassay applications in biotherapeutic workflows.
  • The new Gyrolab Bioaffy 4000, with a 4000 nL sample volume, is based on the proven design of Gyrolab Bioaffy 1000 CD, allowing seamless assay transfer between CD types and enabling researchers to improve productivity.
  • The new CD adds to the Companys existing immunoassay technology, including Gyrolab Bioaffy CDs, which together cover broad analytical ranges of more than 6 logs.
  • Gyrolab Bioaffy 4000 CD is designed to meet customer requests for extended sensitivity for more demanding analytical needs, such as PK (pharmacokinetics) assays requiring higher sensitivity and biomarker quantification.

Global Antimicrobial Resistance Diagnostics Market, Strategies, Trends & Forecasts Report 2021-2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 26, 2021
Health, Other Health, Biochemistry methods, Ion source, Matrix-assisted laser desorption/ionization, Curetis

3.2.8 What Happens to the Microbiology Lab?

Key Points: 

3.2.8 What Happens to the Microbiology Lab?
MALDI-TOF - Results in Minutes, not Days.
Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies